Valcyte: Difference between revisions
From Glioblastoma Treatments
Jump to navigationJump to search
(Created page with "{{TreatmentInfo |drug_name=Valganciclovir (Valcyte) |FDA_approval=Yes (for CMV infections) |used_for=Investigational use in glioblastoma due to potential effects against CMV positive tumors |clinical_trial_phase=Investigational, including early clinical trials |common_side_effects=Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects |OS_without=Median survival with standard treatment: 17.4 months |OS_with=Post-hoc analysis with at least s...") |
No edit summary |
||
| Line 12: | Line 12: | ||
|category=Investigational Drugs | |category=Investigational Drugs | ||
|links= | |links= | ||
|toxicity_level=2 | |||
|toxicity_explanation=The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma. | |||
}} | }} | ||
Revision as of 08:53, 27 March 2024
| Property | Information |
|---|---|
| Drug Name | Valganciclovir (Valcyte) |
| FDA Approval | Yes (for CMV infections) |
| Used for | Investigational use in glioblastoma due to potential effects against CMV positive tumors |
| Clinical Trial Phase | Investigational, including early clinical trials |
| Clinical Trial Explanation | Not specified |
| Common Side Effects | Includes diarrhea, nausea, neutropenia, potential for increased risk of birth defects |
| OS without | Median survival with standard treatment: 17.4 months |
| OS with | Post-hoc analysis with at least six months of Valcyte use: median survival of 24 months, 4-year survival of 27% |
| PFS without | Not specified |
| PFS with | Not directly specified; improvements noted in selected patient analyses |
| Usefulness Rating | 3 |
| Usefulness Explanation | Not specified |
| Toxicity Level | 2 |
| Toxicity Explanation | The drug Valganciclovir (Valcyte) has a relatively low toxicity level. This is measured on a scale between 1 and 5, with 1 being the least toxic and 5 the most toxic. While Valganciclovir is approved by the FDA, it is currently used for the treatment of CMV infections, and its use for glioblastoma is still investigational. Its common side effects include diarrhea, nausea, and neutropenia, which is a lower-than-normal count of neutrophils, a type of white blood cell that helps fight off infections. It also has a potential risk for causing birth defects. The toxicity rating takes into account these potential side effects and the current state of research on its use in treating glioblastoma. |
Notes: Valganciclovir, an anti-CMV drug, has been explored for glioblastoma treatment due to the majority of these tumors being positive for CMV proteins. Initial studies suggest a possible therapeutic benefit, especially with long-term use, but results require further validation through rigorously designed clinical trials to conclusively determine efficacy and optimal usage in glioblastoma treatment.
From Ben Williams Book: Not specified
Loading comments...
